ArticleInternational journal of nanomedicine2026
Oral Microcapsules Encapsulating Endometrial Regenerative Cell-Derived Exosomes Promote Intestinal Epithelial Barrier Repair and Ameliorate Experimental Colitis.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oral Chitosan-Tripolyphosphate Nanoparticles Enhance the Metabolic Regulatory Effects of Snow Lotus Polysaccharide in Type 2 Diabetes.Pharmaceutics · 2026Article
- Gut microbiota-immune crosstalk in osteoarthritis: pathogenic mechanisms and emerging therapeutic opportunities.Frontiers in microbiology · 2026Review
- Unraveling the pleiotropic roles of the mTOR-glycolytic axis in ulcerative colitis: from immunometabolic dysregulation to mucosal barrier remodeling.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial regenerative cell-derived exosomes (ERC-Exos) exhibit tissue repair and anti-inflammatory properties for ulcerative colitis (UC) treatment, but oral administration is limited by gastrointestinal degradation. This study first developed chitosan-sodium alginate microcapsules (CSE) for ERC-Exos delivery and explored the role of milk fat globule-EGF factor 8 (MFGE8). Methods: MFGE8-knockdown ERC-Exos (MFGE8 Results: CSE achieved 89.2%±1.5% encapsulation efficiency and 78% colon-targeted release, resisting gastric degradation. Oral CSE significantly alleviated DSS-induced weight loss ( Conclusion: This study is the first to confirm that the CSE carrier achieves colonic targeted release, overcoming the limitations of oral exosome delivery. MFGE8 mediates the intestinal epithelial repair effect of ERC-Exos via the PI3K/AKT/mTOR pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.